Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

Completed · Phase 3

Conditions studied: Scalp Psoriasis

In brief

This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.

Key facts

Study ID

NCT05028582

Run by

Arcutis Biotherapeutics, Inc.

People needed

432

Starts

2021-08-24

Expected to finish

2022-06-03

Last updated by the study team

2025-07-17

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• For adult subjects: Participants legally competent to read, write, and sign and give informed consent. For adolescent subjects: Informed consent of a parent(s) or legal guardian, and assent by the subjects, as required by local laws.
• Males and females ages 12 years and older (inclusive) at the time of consent or assent.
• Scalp psoriasis with a Scalp-Investigator Global Assessment of Disease (S IGA) severity of at least Moderate ('3') at Baseline.
• Extent of scalp psoriasis involving ≥ 10% of the total scalp at Baseline.
• A Psoriasis Scalp Severity Index (PSSI) of at least 6 at Baseline.
• An IGA of body (i.e., non-scalp) psoriasis (B-IGA) of at least Mild ('2') at Baseline.
• A PASI score of at least 2 (excluding palms and soles) at Baseline.
• Clinical diagnosis of psoriasis vulgaris of at least 6 months duration at Screening as determined by the Investigator. Stable disease for the past 4 weeks.
• Total overall psoriasis involvement on scalp and non-scalp areas ≤ 25% BSA (not including palms/soles) at Baseline. Total non-scalp BSA should not exceed 20%.
• Female subject of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and negative urine pregnancy test at Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception or a barrier method of contraception throughout the study according to Contraception Requirements for the protocol.
• Females of non-childbearing potential must either be premenarchal, post-menopausal with spontaneous amenorrhea for at least 12 months (post-menopausal status will be confirmed with FSH testing) or have undergone surgical sterilization according to Contraception Requirements for the protocol. Prepubescent females must agree to be abstinent during the study.
• Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.

You may not qualify if…

• Subjects who cannot discontinue treatment with therapies for the treatment of psoriasis vulgaris prior to the Baseline visit and during the study.
• Planned excessive exposure to treated area(s) to either natural or artificial sunlight, tanning bed, or other LED.
• Previous treatment with ARQ-151 or ARQ-154.
• Females who are pregnant, wishing to become pregnant during the study, or are breast feeding.
• Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
• Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members residing in the same household of enrolled subjects.
• Any condition that in the Investigator's assessment would preclude the subject from participating in the study.

Where it is running

• Arcutis Biotherapeutics Clinical Site 01 — Scottsdale, Arizona, United States
• Arcutis Biotherapeutics Clinical Site 50 — Beverly Hills, California, United States
• Arcutis Biotherapeutics Clinical Site 45 — Encinitas, California, United States
• Arcutis Biotherapeutics Clinical Site 64 — San Diego, California, United States
• Arcutis Biotherapeutics Clinical Site 72 — Santa Ana, California, United States
• Arcutis Biotherapeutics Clinical Site 21 — Santa Monica, California, United States
• Arcutis Biotherapeutics Clinical Site 33 — Clearwater, Florida, United States
• Arcutis Biotherapeutics Clinical Site 42 — Coral Gables, Florida, United States
• Arcutis Biotherapeutics Clinical Site 57 — Delray Beach, Florida, United States
• Arcutis Biotherapeutics Clinical Site 31 — North Miami Beach, Florida, United States
• Arcutis Biotherapeutics Clinical Site 05 — Orlando, Florida, United States
• Arcutis Biotherapeutics Clinical Site 65 — Sanford, Florida, United States
• Arcutis Biotherapeutics Clinical Site 12 — Tampa, Florida, United States
• Arcutis Biotherapeutics Clinical Site 22 — Plainfield, Illinois, United States
• Arcutis Biotherapeutics Clinical Site 10 — Rolling Meadows, Illinois, United States
• Arcutis Biotherapeutics Clinical Site 15 — Louisville, Kentucky, United States
• Arcutis Biotherapeutics Clinical Site 04 — Lake Charles, Louisiana, United States
• Arcutis Biotherapeutics Clinical Site 02 — Rockville, Maryland, United States
• Arcutis Biotherapeutics Clinical Site 28 — Rockville, Maryland, United States
• Arcutis Biotherapeutics Clinical Site 20 — Detroit, Michigan, United States
• Arcutis Biotherapeutics Clinical Site 14 — New Brighton, Minnesota, United States
• Arcutis Biotherapeutics Clinical Site 44 — Saint Joseph, Missouri, United States
• Arcutis Biotherapeutics Clinical Site 34 — East Windsor, New Jersey, United States
• Arcutis Biotherapeutics Clinical Site 51 — Rochester, New York, United States
• Arcutis Biotherapeutics Clinical Site 63 — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.